Ascendis Pharma A/S (NASDAQ: ASND) is a Danish biopharmaceutical company developing long-acting prodrug therapies using its TransCon™ platform. Its approved product, Skytrofa, targets growth hormone deficiency, while its pipeline includes endocrinology and oncology assets. Ascendis is a high-profile biotech growth name with late-stage catalysts and commercial ramp-up underway.
Последние статьи по акциям